RT Journal Article
SR Electronic
T1 Protection afforded by post-infection SARS-CoV-2 vaccine doses: a cohort study in Shanghai
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.01.09.24301069
DO 10.1101/2024.01.09.24301069
A1 Zheng, Bo
A1 Gonçalves, Bronner
A1 Deng, Pengfei
A1 Wang, Weibing
A1 Tian, Jie
A1 Liang, Xueyao
A1 Yao, Ye
A1 Xue, Caoyi
YR 2024
UL http://medrxiv.org/content/early/2024/05/09/2024.01.09.24301069.abstract
AB Background In many settings, a large fraction of the population has both been vaccinated against and infected by SARS-CoV-2. Hence, quantifying the protection provided by post-infection vaccination has become critical for policy. We aimed to estimate the protective effect against SARS-CoV-2 reinfection of an additional vaccine dose after an initial Omicron variant infection.Methods We report a retrospective, population-based cohort study performed in Shanghai, China, using electronic databases with information on SARS-CoV-2 infections and vaccination history. We compared reinfection incidence by post-infection vaccination status in individuals initially infected during the April-May 2022 Omicron variant surge in Shanghai and who had been vaccinated before that period. Cox models were fit to estimate adjusted hazard ratios (aHR).Results 275,896 individuals were diagnosed with RT-PCR-confirmed SARS-CoV-2 infection in April-May 2022; 199,312/275,896 were included in analyses on the effect of a post-infection vaccine dose. Post-infection vaccination provided protection against reinfection (aHR 0.82; 95% CI 0.79-0.85). For patients who had received one, two or three vaccine doses before their first infection, hazard ratios for the post-infection vaccination effect were 0.84 (0.76-0.93), 0.87 (0.83-0.90) and 0.96 (0.74-1.23), respectively. Post-infection vaccination within 30 and 90 days before the second Omicron wave provided different degrees of protection (in aHR): 0.51 (0.44-0.58), and 0.67 (0.61-0.74), respectively. Moreover, for all vaccine types, but to different extents, a post-infection dose given to individuals who were fully vaccinated before first infection was protective.Conclusions In previously vaccinated and infected individuals, an additional vaccine dose provided protection against Omicron variant reinfection. These observations will inform future policy decisions on COVID-19 vaccination in China and other countries.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was granted by the Key Discipline Program of Pudong New Area Health System [Grant No. PWZxk2022-25]; the Development and Application of Intelligent Epidemic Surveillance and Artificial Intelligence Analysis System [Grant No. 21002411400]; the Shanghai Three-year Action Plan to Strengthen the Construction of Public Health System [Grant No. GWVI-11.2-XD08]. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethical Review Committee in the Shanghai Pudong New Area Center for Disease Control and Prevention (approval number: PDCDCLL-20220801-001).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe individual-level data used in this study are sensitive and cannot be publicly shared. Requests for data should be made to the Shanghai Pudong New Area Center for Disease Control and Prevention.